For many working to end #malaria, the fight is personal. Dr Manyando’s experience with severe malaria inspired her to make a difference for those most at risk. Now, she's leading the SEMA ReACT consortium to improve treatment for children in hard-to-reach communities. #IWD26
Clinical research has long treated pregnant women as a risk to be avoided. Yet exclusion increases risk, especially when #malaria during pregnancy can be deadly. On #IWD26, we call for protecting pregnant women through clinical trials, not from them: bit.ly/4u69dcc
Pregnant women are the group most impacted by #malaria after children. As a nurse treating malaria in pregnancy, Judith Ongeta contributed to the MiMBa pregnancy registry, gathering data on how medicines are used during pregnancy to inform treatment decisions & outcomes. #IWD26
When Dianah had #malaria during pregnancy, two lives were at risk, hers and her baby’s. For too long, pregnant & breastfeeding women have been excluded from research. Our MiMBa strategy is changing that. On #IWD26, we call for inclusive research that responds to the needs of all at-risk populations.
Team MMV, united in the fight for gender equity in #malaria research. Women are central to the fight: as patients, scientists and healthcare professionals. On #IWD26, we're celebrating the teams helping shape solutions and accelerating progress towards a malaria-free future.
Ahead of International Women's Day, we speak with Dr Delese Mimi Darko, Director General of the AMA
🗣️ ‘Women often face invisible barriers: limited access to networks, fewer sponsorships, and expectation to prove readiness.’
🔗 Interview: www.global-health-edctp3.europa.eu/news-and-eve...
#IWD2026
How can #malaria programmes navigate funding challenges? At last week’s SMC Alliance & Alliance for Malaria Prevention meeting, Catherine Pitt of @lshtm.bsky.social discussed the need to rethink funding decisions, using economic evaluations to prioritize impact: bit.ly/3P2LVUx
Leadership matters most when research needs to translate into action.
Congrats to Marcus Lacerda on his appointment as Director of @who.int TDR, where he’ll help advance the organization’s strategy of building locally driven research to address global health problems.
In case you missed it: new evidence on the value of investing in #malaria #innovation through MMV. Between 2000 and 2023, these investments delivered 13x their value in health benefits, with a 52% return per year. More people protected & more lives saved: bit.ly/4r59Ikm
When researchers gain access to new collaborations & expertise, the impact goes beyond a single project. Dr Cheuka shares how his work through our African call for proposals moved his team closer to identifying novel molecules for #malaria interventions: bit.ly/3MRp1ik
This week, the SMC Alliance and the Alliance for Malaria Prevention are holding a joint annual meeting in Kampala. Partners, including MMV, are sharing lessons and shaping the next phase of #malaria prevention through preventive medicines and insecticide-treated nets.
Marine sponges could hold the starting points for next-generation antimalarials. Dr Godwin Akpeko Dziwornu shares how his MMV-funded research is exploring sponge-derived compounds to inform #malaria drug discovery: bit.ly/3MRp1ik
Last call: MMV’s 23rd Call for proposals closes this Friday. Help us shape the next generation of #malaria meds. We’re looking for compounds addressing key prevention, treatment & elimination needs, including innovative biology beyond small molecules 👉 bit.ly/3XFUG8n
Malaria control is entering a new phase, with stronger country-led efforts key to protecting more people. A report from @malarianomore.org and @beatmalaria.bsky.social explores how data-driven planning, sustainable financing and partnerships can support country-led responses: bit.ly/4rgP6GJ
Long-term investment in #malaria innovation pays off in measurable ways. A @thelancet.com study (2000-2023) finds investments in MMV deliver 13× their value in health benefits. See why PDPs like MMV offer a proven model for global health investment: bit.ly/4aC2yhh
Time and cost are often the biggest barriers in early drug discovery, especially for researchers in endemic settings.
@suhealthsci.bsky.social postdoc Jessica Thibaud says MMV & @deepmirror.bsky.social’s dd4gh could change early-stage computational studies. 🎥
MMV CEO Martin Fitchet has been named to the @time.com 100 list of the most influential people in health for 2026. A recognition that reflects the progress being made across the global #malaria community, and the partnerships behind it. 🔗 bit.ly/4aak1yf
Women are shaping the discovery, development and delivery of next-generation #malaria interventions.
Today, we’re spotlighting six #WomenInScience from MMV’s network making their mark on global health: bit.ly/4apwjBA
AI in drug discovery only matters if scientists in high-burden settings can use it. Last December, African researchers tested MMV & @deepmirror.bsky.social's dd4gh platform. PhD computational analyst Caroline Maina says it could help identify promising TB compounds.
At this week's @who.int Executive Board, MMV delivered statements on key #malaria priorities: keeping malaria central to the 2030 Sustainable Development Agenda, tackling drug resistance & advancing Indigenous-centred elimination strategies. Read them here 👉 bit.ly/4qhaDhd
With antimalarial drug resistance mounting, ganaplacide-lumefantrine could make a major difference in the fight against #malaria. @malarianomore.org spoke with Caroline Boulton of
@novartis.bsky.social about the journey of this drug and the promise it brings 👉 bit.ly/3LlMBmN
Malaria eradication is a global health priority and a compelling economic one.
While we can develop next-gen #malaria tools, financing and delivery remain a challenge. Management Sciences for Health
discusses why bridging the gap between innovation and investment matters 👉 bit.ly/4qtqLga
Diversifying antimalarial drug use across Africa can slow resistance & help prevent rising treatment failures. In
@science.org, researchers lay out practical resistance mitigation steps & why the next decade will be critical for #malaria management 👉 bit.ly/49XX1Cg
MMV is partnering with the University of Ghana's Noguchi Memorial Institute for Medical Research (NMIMR) to accelerate new #malaria treatments and strengthen Africa-led antimalarial drug discovery. Learn more 👉 bit.ly/4qkfyOW
Antimalarial drug resistance threatens decades of progress against #malaria. Acting early matters.
Protect the Cure is a documentary that explores the science, human impact and solutions behind the growing resistance crisis 👉 bit.ly/494TD8s
Our response to antimalarial drug resistance will shape the future of #malaria control & elimination. Ganaplacide-lumefantrine, a novel non-artemisinin combination developed by @novartis.bsky.social with MMV, can tackle drug-resistant parasites. Prof. Djimdé explains how on BBC
👉 bit.ly/4qaHQLU
Calling all mid-career African researchers: the application deadline for the SAHRI Fellowship Programme is fast approaching. A fully funded opportunity to build leadership in biomedical innovation and clinical research. Apply by 1 February bit.ly/4qfTdT6
Can #AI accelerate the discovery of next-gen antimalarials to keep us ahead of resistance and bring us closer to zero #malaria deaths? Sithulisiwe Ngwenya explains how dd4gh, an AI-powered platform in development by MMV & @deepmirror.bsky.social, can support her drug discovery research.
This Sunday, graduate researcher Camille Gourjault is taking the fight against #malaria from the lab to the streets, where he'll be running in the Hong Kong Marathon in support of MMV’s mission to discover, develop and deliver the next generation of antimalarials. Learn more 👉 bit.ly/3LJ3esD
